MCID: PRN020
MIFTS: 40

Paranasal Sinus Cancer

Categories: Cancer diseases, Rare diseases, Respiratory diseases, Skin diseases

Aliases & Classifications for Paranasal Sinus Cancer

MalaCards integrated aliases for Paranasal Sinus Cancer:

Name: Paranasal Sinus Cancer 12 15 70
Paranasal Sinus Adenoid Cystic Carcinoma 12 17 70
Paranasal Sinus Mucoepidermoid Carcinoma 12 70
Paranasal Sinus Squamous Cell Carcinoma 12 70
Paranasal Sinus Neoplasms 44 70
Adenoid Cystic Carcinoma of Accessory Sinus 12
Adenoid Cystic Carcinoma of Paranasal Sinus 12
Epidermoid Carcinoma of the Paranasal Sinus 12
Mucoepidermoid Carcinoma of Accessory Sinus 12
Squamous Cell Carcinoma of Paranasal Sinus 12
Adenocarcinoma of Accessory Sinus 70
Paranasal Sinus Adenocarcinoma 12
Paranasal Sinus Neoplasm 17

Classifications:



External Ids:

Disease Ontology 12 DOID:0050619
MeSH 44 D010255
UMLS 70 C0030470 C0280334 C0854995 more

Summaries for Paranasal Sinus Cancer

Disease Ontology : 12 A respiratory system cancer that is located in the paranasal sinuses.

MalaCards based summary : Paranasal Sinus Cancer, also known as paranasal sinus adenoid cystic carcinoma, is related to paranasal sinus cancer, adult and sinus cancer, and has symptoms including pain and rhinorrhea. An important gene associated with Paranasal Sinus Cancer is MIR299 (MicroRNA 299), and among its related pathways/superpathways are Circadian rythm related genes and Proteoglycans in cancer. The drugs Fluorouracil and Docetaxel have been mentioned in the context of this disorder. Affiliated tissues include paranasal sinuses, endothelial and liver, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Related Diseases for Paranasal Sinus Cancer

Diseases in the Paranasal Sinus Cancer family:

Paranasal Sinus Cancer, Adult

Diseases related to Paranasal Sinus Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 39)
# Related Disease Score Top Affiliating Genes
1 paranasal sinus cancer, adult 11.5
2 sinus cancer 10.7
3 adenoid cystic carcinoma 10.4
4 spastic paraplegia, intellectual disability, nystagmus, and obesity 10.1
5 adenocarcinoma 10.1
6 nemaline myopathy 10.1 MIR409 MIR299 MIR127
7 muscular dystrophy, duchenne type 10.0 MIR409 MIR299 MIR127
8 hemangioma 10.0
9 capillary hemangioma 10.0
10 rhabdomyosarcoma 10.0
11 diabetes insipidus 10.0
12 headache 10.0
13 exophthalmos 10.0
14 nasal cavity cancer 10.0
15 ethmoid sinus cancer 10.0
16 squamous cell papilloma 10.0
17 squamous cell carcinoma 10.0
18 melanoma 10.0
19 papilloma 10.0
20 ethmoid sinus adenocarcinoma 10.0
21 inverted papilloma 10.0
22 olfactory neuroblastoma 10.0
23 maxillary cancer 10.0
24 nasal cavity squamous cell carcinoma 10.0
25 lip cancer 9.9 TP53 MIR202
26 uterus carcinoma in situ 9.9 TP53 MIR654
27 cervix uteri carcinoma in situ 9.9 TP53 MIR654
28 pre-malignant neoplasm 9.8 TP53 MIR654 MIR299
29 laryngeal disease 9.8 TP53 MIR654 MIR127
30 barrett's adenocarcinoma 9.7 TP53 TAGLN2
31 lobular neoplasia 9.7 TP53 MIR375
32 cervix disease 9.7 TP53 MIR133A1 MIR127
33 pancreas disease 9.7 TP53 MIR202 MIR127
34 esophagus adenocarcinoma 9.7 TP53 TAGLN2
35 nervous system disease 9.6 TP53 MIR874 MIR409 MIR127
36 respiratory system disease 9.4 TP53 MIR409 MIR202 MIR133A1 MIR127
37 maxillary sinus squamous cell carcinoma 9.3 TP53 MIR874 MIR654 MIR409 MIR299 MIR127
38 rasopathy 9.2 TP53 PPP1CB PPP1CA
39 maxillary sinus cancer 8.1 TAGLN2 PPP1CA PNP MIR874 MIR654 MIR409

Graphical network of the top 20 diseases related to Paranasal Sinus Cancer:



Diseases related to Paranasal Sinus Cancer

Symptoms & Phenotypes for Paranasal Sinus Cancer

UMLS symptoms related to Paranasal Sinus Cancer:


pain; rhinorrhea

GenomeRNAi Phenotypes related to Paranasal Sinus Cancer according to GeneCards Suite gene sharing:

26 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-11 9.4 PPP1CB
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-120 9.4 LDHB
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-142 9.4 PPP1CB
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-159 9.4 PPP1CB
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 9.4 PPP1CB
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-177 9.4 PPP1CB
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-191 9.4 LDHB
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-197 9.4 LDHB
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-204 9.4 LDHB
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-214 9.4 PPP1CB
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-57 9.4 LDHB PPP1CB

Drugs & Therapeutics for Paranasal Sinus Cancer

Drugs for Paranasal Sinus Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 72)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluorouracil Approved Phase 3 51-21-8 3385
2
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
3
Hydroxyurea Approved Phase 3 127-07-1 3657
4 Immunosuppressive Agents Phase 3
5 Antimetabolites Phase 3
6
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
7
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
8
Irinotecan Approved, Investigational Phase 2 100286-90-6, 97682-44-5 60838
9
Bevacizumab Approved, Investigational Phase 1, Phase 2 216974-75-3
10
Bortezomib Approved, Investigational Phase 2 179324-69-7 93860 387447
11
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
12
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
13 Raspberry Approved Phase 1, Phase 2
14
Lapatinib Approved, Investigational Phase 2 231277-92-2, 388082-78-8 208908 9941095
15
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
16
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
17
Etoposide Approved Phase 2 33419-42-0 36462
18
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
19
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
20
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
21
Selenium Approved, Investigational, Vet_approved Phase 2 7782-49-2
22
Saracatinib Investigational Phase 2 379231-04-6
23
Pyrazole Experimental Phase 2 288-13-1
24 Tubulin Modulators Phase 1, Phase 2
25 Antimitotic Agents Phase 1, Phase 2
26 Immunologic Factors Phase 2
27 Protein Kinase Inhibitors Phase 2
28 Epothilones Phase 2
29 Epothilone B Phase 2
30 Lactams Phase 2
31 topoisomerase I inhibitors Phase 2
32 Immunoglobulins Phase 2
33 Mitogens Phase 1, Phase 2
34 Antibodies Phase 2
35 Antineoplastic Agents, Immunological Phase 2
36 Immunoglobulins, Intravenous Phase 2
37 Antibodies, Monoclonal Phase 2
38
Erlotinib Hydrochloride Phase 1, Phase 2 183319-69-9 176871
39 Proteasome Inhibitors Phase 2
40 Albumin-Bound Paclitaxel Phase 2
41 Analgesics, Non-Narcotic Phase 2
42 Cyclooxygenase 2 Inhibitors Phase 2
43 Cyclooxygenase Inhibitors Phase 2
44 Antirheumatic Agents Phase 2
45 Anti-Inflammatory Agents Phase 2
46 Analgesics Phase 2
47 Anti-Inflammatory Agents, Non-Steroidal Phase 2
48 Carbonic Anhydrase Inhibitors Phase 2
49 benzenesulfonamide Phase 2
50 Etoposide phosphate Phase 2

Interventional clinical trials:

(show all 50)
# Name Status NCT ID Phase Drugs
1 A Phase III Randomized Trial of Docetaxel Based Induction Chemotherapy in Patients With N2/N3 Locally Advanced Head and Neck Cancer Completed NCT00117572 Phase 3 docetaxel;cisplatin;hydroxyurea;fluorouracil
2 Phase II Evaluation of BAY 43-9006 (NSC-724772) in Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00096512 Phase 2 sorafenib tosylate
3 A Randomized Phase II Study of BMS-247550 (NSC #710428) Given Daily x 5 Days Every 3 Weeks or Weekly in Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck Completed NCT00033618 Phase 2 ixabepilone
4 Phase I/II Dose Escalation Trial of Induction and Concomitant Erlotinib and Celecoxib With Radiation Therapy for Treatment of Poor Prognosis Head and Neck Cancer, Including Reirradiation Completed NCT00970502 Phase 1, Phase 2 erlotinib + celecoxib
5 Phase II Two Arm Trial of the Proteasome Inhibitor, PS-341 (Velcade TM) in Combination With Irinotecan or PS-341 Alone Followed by the Addition of Irinotecan at Time of Progression in Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Completed NCT00103259 Phase 2 bortezomib;irinotecan hydrochloride
6 Phase II Study of Concomitant Fluorouracil, Hydroxyurea, Cetuximab and Hyperfractionated Intensity Modulated Radiation Therapy for Locally Advanced Head and Neck Cancer Completed NCT00462735 Phase 2 Cetuximab;Hydroxyurea;Fluorouracil
7 Phase II Study of Sunitinib Malate in Head and Neck Squamous Cell Carcinoma Completed NCT00387335 Phase 2 sunitinib malate
8 A Phase I, and Biologic Correlative Study of Erlotinib, in Combination With Cetuximab and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma Completed NCT00101348 Phase 1, Phase 2 erlotinib hydrochloride
9 A Phase I/II Study Of Bevacizumab (rhuMAb VEGF) In Combination With OSI-774 For Patients With Recurrent Or Metastatic Cancer Of The Head And Neck Completed NCT00055913 Phase 1, Phase 2 erlotinib hydrochloride
10 A Phase I and Phase II Study of OSI-774 in Combination With Docetaxel in Squamous Cell Carcinoma of the Head and Neck Completed NCT00055770 Phase 1, Phase 2 erlotinib hydrochloride;docetaxel
11 Food-Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer Completed NCT01469429 Phase 1, Phase 2 chemoprevention;chemoprevention
12 A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage Completed NCT00492089 Phase 2 bevacizumab;placebo
13 A Phase 2 Trial of GW572016 in Patients With Metastatic and Recurrent Squamous Cell Carcinomas of the Head and Neck Completed NCT00114283 Phase 2 lapatinib ditosylate
14 A Phase II Study Of GW572016 In Squamous Cell Carcinoma Of The Head And Neck (SCCHN) Completed NCT00098631 Phase 2 lapatinib ditosylate
15 A Phase 2 Study of SB-715992 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Completed NCT00095628 Phase 2 ispinesib
16 A Phase 2 Study of Dasatinib in Head and Neck Squamous Cell Carcinoma Completed NCT00507767 Phase 2 dasatinib
17 A Phase II Study of Capecitabine and Lapatinib in Squamous Cell Carcinoma of the Head and Neck Completed NCT01044433 Phase 2 lapatinib ditosylate;capecitabine
18 Phase II Trial of Carboplatin/Paclitaxel and Cetuximab, Followed by Carboplatin/Paclitaxel/Cetuximab and Erlotinib, With Correlative Studies in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck. Completed NCT01316757 Phase 2 paclitaxel;carboplatin;erlotinib hydrochloride
19 Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab in Patients With Refractory, Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Completed NCT00939627 Phase 2 sorafenib tosylate
20 A Phase II Study of AZD0530 for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Completed NCT00513435 Phase 2 saracatinib
21 Phase II Trial of Induction Therapy With Docetaxel, Cisplatin and Fluorouracil in Previously Untreated Patients With Locally Advanced Squamous Cell Carcinoma and/or Poorly Differentiated Carcinoma of the Nasal Cavity and/or Paranasal Sinuses Recruiting NCT00707473 Phase 2 Carboplatin;Cisplatin;Docetaxel;Fluorouracil
22 Phase II Randomized Trial of Neo-Adjuvant Chemotherapy Followed by Surgery and Post-Operative Radiation Versus Surgery and Post-Operative Radiation for Organ Preservation of T3 and T4a Nasal and Paranasal Sinus Squamous Cell Carcinoma (NPNSCC) Recruiting NCT03493425 Phase 2 Carboplatin;Cisplatin;Docetaxel
23 RESILIENCE: Effect of Comprehensive Celecoxib Through Treatment for Advanced-Stage Head and Neck Cancer: A Randomized, Double-Blinded, Placebo-Controlled Trial Recruiting NCT04162873 Phase 2 Celecoxib
24 A Phase II, Single-Arm Trial Assessing Local Control of Near Total Endoscopic Resection Followed by Concurrent Chemotherapy and Proton Radiation in the Treatment of Unresectable Sinonasal Tumors Active, not recruiting NCT03274414 Phase 2 Cisplatin;cisplatin and etoposide
25 A Prospective Non-Inferiority Trial of the Use of Adaptive Radiotherapy for Head and Neck Cancer Undergoing Radiation Therapy Active, not recruiting NCT03096808 Phase 2
26 A Biomarker Driven Pilot Study of the Pan-class I PI3K Inhibitor NVP-BKM120 in Combination With Cetuximab in Patients With Recurrent/Metastatic Head and Neck Cancer Active, not recruiting NCT01816984 Phase 1, Phase 2 PI3K inhibitor BKM120
27 A Phase II Study of Vorinostat and Capecitabine in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) and Nasopharyngeal Carcinoma (NPC) Terminated NCT01267240 Phase 2 Capecitabine;Vorinostat
28 Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase II Trial of Selenomethionine as a Modulator of Efficacy and Toxicity of Chemoradiation in Locally-Advanced Squamous Cell Carcinoma of the Head and Neck Terminated NCT01682031 Phase 2 cisplatin
29 A Phase 2 Placebo Controlled Randomized Study of the Effect of SAMITAL on Severity and Duration of Mucositis Induced by Chemoradiation for Head and Neck Cancer (HNC) Withdrawn NCT01674374 Phase 2 Vaccinium myrtillus/Macleaya cordata/Echinacea angustifolia extract granules
30 Phase 1 Study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG, NSC #707545) in Patients With Solid Tumors. Completed NCT00089362 Phase 1 alvespimycin hydrochloride
31 A Phase I Study of UCN-01 in Combination With Irinotecan in Resistant Solid Tumor Malignancies (Part I) and in Triple Negative (ER-Negative, PgR-Negative, HER-2 Not-Amplified) Recurrent Breast Cancers (Part II) Completed NCT00031681 Phase 1 7-hydroxystaurosporine;irinotecan hydrochloride
32 A Phase I Study Of Bevacizumab (Recombinant Humanized Monoclonal Antibody To Vascular Endothelial Growth Factor) In Addition To Flourouracil And Hydroxyurea As Initial Chemotherapy With Concomitant Radiotherapy (B-FHX) For Poor Prognosis Head And Neck Cancer Completed NCT00023959 Phase 1 hydroxyurea;fluorouracil
33 A Phase I Study of Surgery Plus Intraoperative Photodynamic Therapy (PDT) in Patients With Resectable, Primary or Recurrent Head and Neck Cancer Completed NCT00470496 Phase 1 HPPH;photodynamic therapy
34 A Phase I Clinical and Biological Evaluation of Combined EGFR Blockade With Erlotinib and Cetuximab in Patients With Advanced Cancer Completed NCT00397384 Phase 1 cetuximab;erlotinib hydrochloride
35 Phase I Study of OSI-774 (NSC 718781) for Solid Tumors in Patients With Hepatic or Renal Dysfunction Completed NCT00030498 Phase 1 erlotinib hydrochloride
36 Phase I Clinical Trial of VTX-2337, a Small Molecule Toll-Like Receptor 8 (TLR8) Agonist in Combination With Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinomas of the Head and Neck (SCCHN) Completed NCT01334177 Phase 1 TLR8 agonist VTX-2337
37 A Phase I/II Clinical Trial of Sorafenib in Combination With Cisplatin and Docetaxel in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Completed NCT02035527 Phase 1 sorafenib tosylate;cisplatin;docetaxel
38 A Phase I Evaluation of Cetuximab and RAD001 in Patients With Solid Tumors Completed NCT01637194 Phase 1 everolimus
39 A Phase 1 Study of Paclitaxel and Carboplatin in Solid Tumors (With Focus on Upper Aerodigestive Cancers) in Persons With HIV Infection Terminated NCT01249443 Phase 1 vorinostat;carboplatin;paclitaxel
40 A Phase I Study Of PV701 In Patients With Head And Neck Squamous Cell Carcinoma Terminated NCT00081211 Phase 1
41 A Phase I Trial of Concurrent Chemoradiation/Chemoreirradiation With Cetuximab (ERBITUX®), Sunitinib, and Accelerated Radiation in Patients With Locally Advanced/High-risk/Recurrent Poor Prognosis Head and Neck Cancer Terminated NCT00906360 Phase 1 sunitinib malate
42 A Phase Ib Immunomodulatory Study of Single Agent Talactoferrin in Patients With Select Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC) and Squamous Head and Neck Cancer (HNSCC) Terminated NCT01528137 Phase 1
43 A Phase I Study of CBLB502 in the Treatment of Patients With Poor Prognosis Advanced Squamous Cell Carcinomas of the Head and Neck Receiving Chemoradiotherapy Withdrawn NCT01728480 Phase 1 entolimod;cisplatin
44 Single Agent ZD-1839 (NSC-715055, IND-61187) in Patients With Advanced Head and Neck Carcinoma or Non-Small Cell Lung Cancer Aged 75 Years and Older (and in a Cohort of Patients 50 Years Old and Younger) Completed NCT00068497 gefitinib
45 A Clinical Outcomes Protocol of Photon/Proton Beam Radiation Therapy for Cancers of the Nasal Cavity and/or Paranasal Sinuses Completed NCT00797498
46 A Pilot Study to Evaluate the Predictive Value of Circulating Tumor DNA for Clinical Outcome in Patients With Advanced Head and Neck and Lung Cancers Recruiting NCT02245100
47 Integrated Cancer Repository for Cancer Research Recruiting NCT02012699
48 The Utility of Indocyanine Green Fluorescence in Endoscopic Sinonasal and Skull Base Surgery - A Prospective Case-Series and Feasibility Study Not yet recruiting NCT04374448
49 Olfactory Training For Post Radiation Olfactory Loss In Patients With Paranasal Sinus and Nasopharyngeal Carcinoma Terminated NCT03049358
50 Preoperative Radiotherapy and Concomitant Chemotherapy Followed by Surgery for Advanced Paranasal Sinus Carcinoma Withdrawn NCT00347256 cisplatin

Search NIH Clinical Center for Paranasal Sinus Cancer

Cochrane evidence based reviews: paranasal sinus neoplasms

Genetic Tests for Paranasal Sinus Cancer

Anatomical Context for Paranasal Sinus Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Paranasal Sinus Cancer:

19
Paranasal Sinuses

MalaCards organs/tissues related to Paranasal Sinus Cancer:

40
Endothelial, Liver, Eye, Salivary Gland, Neutrophil

Publications for Paranasal Sinus Cancer

Articles related to Paranasal Sinus Cancer:

(show top 50) (show all 69)
# Title Authors PMID Year
1
The incidence of myocardial infarction and stroke in head and neck cancer patients. 61
33603026 2021
2
PI3K/AKT/mTOR pathway and autophagy regulator genes in paranasal squamous cell carcinoma metastasis. 61
32319010 2020
3
Sinonasal Undifferentiated Carcinoma in a Patient Previously Treated for an Intestinal-Type Adenocarcinoma: Metachronous Neoplasms or Recurrence of a Different Tumor Type? 61
31763244 2019
4
Review of carcinogenicity of hexavalent chrome and proposal of revising approval standards for an occupational cancers in Korea. 61
29423230 2018
5
Results of preoperative chemoradiotherapy for patients with advanced cancer of the nasal cavity and paranasal sinuses. 61
28749194 2017
6
Prognostic value of pretreatment peripheral blood markers in paranasal sinus cancer: Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio. 61
28032937 2017
7
Chronic Sinusitis and Risk of Head and Neck Cancer in the US Elderly Population. 61
27606895 2017
8
[Nasal cavity and paranasal sinus cancer]. 61
27528562 2016
9
Impact of Endoscopic Indocyanine Green Fluorescence Imaging on Superselective Intra-arterial Chemotherapy for Recurrent Cancer of the Skull Base. 61
27354602 2016
10
Paranasal sinus cancer. 61
26520459 2016
11
Estimation of the planning organ at risk volume for the lenses during radiation therapy for nasal cavity and paranasal sinus cancer. 61
26238510 2015
12
Significant improvement in superselective intra-arterial chemotherapy for advanced paranasal sinus cancer by using indocyanine green fluorescence. 61
24318470 2014
13
Dose distribution resulting from changes in aeration of nasal cavity or paranasal sinus cancer in the proton therapy. 61
25245554 2014
14
A dosimetric comparison of volumetric modulated arc therapy (VMAT) and non-coplanar intensity modulated radiotherapy (IMRT) for nasal cavity and paranasal sinus cancer. 61
25175383 2014
15
Paranasal sinus cancer. 61
23523040 2013
16
Cranial Nerves Contouring Among Patients Treated With IMRT for Base of Skull, Nasopharyngeal, and Paranasal Sinus Cancer. 61
24674554 2013
17
Non-coplanar volumetric modulated arc therapy for irradiation of paranasal sinus tumors: in response to Al-Mamgani et al., Highly-conformal intensity-modulated radiotherapy reduced toxicity without jeopardizing outcome in patients with paranasal sinus cancer treated by surgery and radiotherapy or (chemo)radiation. Oral Oncol 2012;48(9):905-11. 61
23218179 2013
18
Highly-conformal intensity-modulated radiotherapy reduced toxicity without jeopardizing outcome in patients with paranasal sinus cancer treated by surgery and radiotherapy or (chemo)radiation. 61
22584070 2012
19
The potential benefit of radiotherapy with protons in head and neck cancer with respect to normal tissue sparing: a systematic review of literature. 61
21349950 2011
20
[Brachytherapy in combination with function-preserving surgery of cancer of the paranasal sinus]. 61
20352601 2010
21
Head and neck cancer in Germany: a site-specific analysis of survival of the Thuringian cancer registration database. 61
19568769 2010
22
Primary carcinoma of the frontal sinus: a case report and a review of literature. 61
17952448 2008
23
Fistula formation after postoperative radiation treatment for paranasal sinus cancer. 61
18391607 2008
24
[Results of treatment in patients with paranasal sinus carcinoma. Analysis of prognostic factors]. 61
18637419 2008
25
[Surgical management of minor salivary gland tumors]. 61
18309648 2007
26
[Revision of carcinomas in paranasal sinuses]. 61
17663948 2007
27
Treatment of nasal cavity and paranasal sinus cancer with modern radiotherapy techniques in the postoperative setting--the MSKCC experience. 61
17161557 2007
28
A dosimetric comparison of non-coplanar IMRT versus Helical Tomotherapy for nasal cavity and paranasal sinus cancer. 61
17275112 2007
29
[Invasion of the orbit in paranasal sinus tumours]. 61
18552015 2007
30
[Epidemiology of nasal and paranasal sinus cancer in Tunisia]. 61
16840900 2006
31
Effectiveness of noncoplanar IMRT planning using a parallelized multiresolution beam angle optimization method for paranasal sinus carcinoma. 61
16168851 2005
32
Intra-arterial cisplatin and concomitant radiation therapy followed by surgery for advanced paranasal sinus cancer. 61
15313865 2004
33
Paranasal sinus cancer. 61
15185004 2004
34
The delivery of IMRT with a single physical modulator for multiple fields: a feasibility study for paranasal sinus cancer. 61
14967445 2004
35
Paranasal sinus cancer: caveats and controversies. 61
14509518 2003
36
Comparison of treatment plans using intensity-modulated radiotherapy and three-dimensional conformal radiotherapy for paranasal sinus carcinoma. 61
12694834 2003
37
[Trans-facial and cranio-facial approach and resection of the skull base tumors]. 61
14587388 2003
38
[Usefulness of CT-angiography for superselective intra-arterial chemotherapy for advanced head and neck cancers]. 61
12484060 2002
39
Irradiation of paranasal sinus tumors, a delineation and dose comparison study. 61
11777629 2002
40
An anatomy-based beam segmentation tool for intensity-modulated radiation therapy and its application to head-and-neck cancer. 61
11699497 2001
41
Mortality experience among employees at a hydrometallurgical nickel refinery and fertiliser complex in Fort Saskatchewan, Alberta (1954-95). 61
11600726 2001
42
Frontal sinus adenocarcinoma. 61
10887389 2000
43
Neurocognitive effects of therapeutic irradiation for base of skull tumors. 61
10656372 2000
44
Multimodality therapy in advanced paranasal sinus carcinoma: superior long-term results. 61
10439167 1999
45
Combined-modality therapy in paranasal sinus cancer. 61
10439164 1999
46
Invasive surgery for paranasal sinus cancer: is there still any indication for lateral rhinotomy and non endoscopic approaches? 61
10635392 1999
47
p53 alteration and human papilloma virus infection in paranasal sinus cancer. 61
9083153 1997
48
Prognostic factors in paranasal sinus cancer. 61
7793504 1995
49
Treatment of paranasal sinus cancer with cranial base surgery: results. 61
8189985 1994
50
Craniofacial resection in the management of paranasal sinus cancer. 61
18638740 1994

Variations for Paranasal Sinus Cancer

Expression for Paranasal Sinus Cancer

Search GEO for disease gene expression data for Paranasal Sinus Cancer.

Pathways for Paranasal Sinus Cancer

Pathways related to Paranasal Sinus Cancer according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
2 11.81 TP53 PPP1CB PPP1CA
3
Show member pathways
11.64 TP53 PPP1CB PPP1CA
4 11.52 TP53 PPP1CB PPP1CA
5 11.1 TP53 MIR874 MIR375 MIR127
6 11.06 MIR409 MIR375 MIR127

GO Terms for Paranasal Sinus Cancer

Cellular components related to Paranasal Sinus Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.73 MIR874 MIR654 MIR409 MIR375 MIR133A1 MIR127
2 protein phosphatase type 1 complex GO:0000164 9.16 PPP1CB PPP1CA
3 PTW/PP1 phosphatase complex GO:0072357 8.96 PPP1CB PPP1CA
4 glycogen granule GO:0042587 8.62 PPP1CB PPP1CA

Biological processes related to Paranasal Sinus Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 glycogen metabolic process GO:0005977 9.32 PPP1CB PPP1CA
2 regulation of glycogen biosynthetic process GO:0005979 9.26 PPP1CB PPP1CA
3 gene silencing by miRNA GO:0035195 9.23 MIR874 MIR654 MIR409 MIR375 MIR299 MIR202
4 regulation of glycogen catabolic process GO:0005981 9.16 PPP1CB PPP1CA
5 entrainment of circadian clock by photoperiod GO:0043153 9.13 TP53 PPP1CB PPP1CA

Molecular functions related to Paranasal Sinus Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 8.92 MIR654 MIR409 MIR299 MIR133A1

Sources for Paranasal Sinus Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....